CAR-T CELL THERAPY

This early-phase trial is testing a new treatment called GC012F (CD19-BCMA CAR-T cells) for people with severe lupus that hasn't improved with standard medications. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells driving the disease. T…

This study tests a new treatment called MB-CART2019.1 for people with active multiple sclerosis (MS) that hasn't responded to other therapies. The treatment uses a patient's own immune cells, modified to target and attack harmful immune cells driving MS. The goal is to see if it …

This study looks at whether providing free bags of groceries to patients undergoing stem cell transplants or CAR-T cell therapy can help improve their nutrition and treatment results. Many patients face high medical costs that make it hard to afford enough food, which can hurt th…

This phase 2 trial tests a new CAR T cell therapy called MB-CART2019.1 in 31 people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, genetically modified to target and k…

This early-stage trial is testing a new treatment called TC-D101 CAR-T for people with a specific type of advanced small cell lung cancer that has stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to target cancer cells, and is giv…

This early-stage trial is testing a new treatment called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. A-CAR028 is a type of immune cell therapy (CAR-T) that is designed to recognize and attack leukemia cells by tar…

This study tests a program called Step Up that combines in-person coaching with a mobile app to teach coping skills and encourage physical activity. It includes 177 adults who have had a stem cell transplant or CAR-T therapy for blood cancers like leukemia or multiple myeloma. Th…

This study tests a mobile app called THRIVE-CAR-T designed to support patients during CAR-T cell therapy. Researchers want to see if the app is easy to use and acceptable to patients. About 100 adults with blood cancer receiving CAR-T treatment will participate. The app provides …

This study follows up to 500 people who have received a gene therapy product from Seattle Children's Hospital. Researchers will track participants for 15 years to watch for any delayed side effects and see how long the therapy lasts in the body. No new treatment is given—this is …

This early-stage study explores whether exercise can improve the quality of immune cells collected from healthy donors for blood cancer treatments. Researchers will have healthy volunteers cycle, take a beta blocker or placebo, or receive a drug that mimics adrenaline, then analy…

This study looks at why some people getting CAR T-cell therapy for cancer develop brain-related side effects called neurotoxicity. Researchers will use advanced brain scans, thinking tests, and blood markers to find early warning signs. The goal is to create a tool that identifie…